Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.
No takes yet. Share an insight, caveat, or question.
Kadmon et al. (1991) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: